• Baicalin Restores Visual Plasticity in Adult Amblyopia Model

  2026-07-27

  A recent study demonstrates that Baicalin, a flavone glycoside from Scutellaria baicalensis, reactivates ocular dominance plasticity in adult mice with amblyopia. These findings highlight a promising pharmacological avenue for restoring vision in adults, with implications for neuroplasticity research and translational therapy development.

• Axitinib (AG 013736): Precision VEGFR Inhibition Workflows

  2026-07-26

  Axitinib (AG 013736) offers ultra-selective, sub-nanomolar VEGFR inhibition, enabling researchers to dissect angiogenic signaling and tumor growth with unmatched clarity. Streamline your angiogenesis and xenograft model assays with evidence-driven protocols, troubleshooting tips, and workflow innovations that maximize data fidelity.

• Caspase-3/7 Inhibitor I: Applied Workflows & Troubleshooting

  2026-07-25

  Caspase-3/7 Inhibitor I offers precise, reversible inhibition for dissecting caspase-dependent apoptosis in both basic and translational research. This article details stepwise protocols, advanced experimental use-cases, and practical troubleshooting, with insights directly linked to recent studies of cell death signaling.

• BCA Protein Assay Kit: Optimizing Bicinchoninic Acid Quantif

  2026-07-24

  The BCA Protein Assay Kit from APExBIO delivers ultra-sensitive, robust protein quantification for demanding biochemical workflows. This article bridges innovative findings on alveolar epithelial cell studies with advanced assay protocols, troubleshooting expertise, and actionable optimization strategies.

• Targeting AGTR1 in Armored Tumors Enhances Immune Checkpoint

  2026-07-24

  This study identifies angiotensin II receptor 1 (AGTR1) as a critical target in armored and cold tumors, showing that angiotensin II receptor antagonists suppress tumor fibrosis and sensitize tumors to immune checkpoint blockade. The findings highlight a novel combinatorial strategy for overcoming immunotherapy resistance in collagen-rich, immune-excluded cancers.

• Ionomycin Calcium Salt: Optimizing Calcium Ionophore Workflo

  2026-07-23

  Ionomycin calcium salt stands out as a precision calcium ionophore for elevating intracellular Ca2+ and dissecting apoptosis pathways in cancer research. This article details practical protocols, troubleshooting insights, and cross-study innovations for leveraging ionomycin in advanced cellular signaling and tumor inhibition models.

• Y-27632: Practical Guide for ROCK Inhibitor Workflows

  2026-07-23

  Y-27632 addresses the need for precise and selective modulation of ROCK1 and ROCK2 activity in cell biology, enabling controlled study of cytoskeletal dynamics and the ROCK signaling pathway. It is best applied in workflows requiring reversible inhibition of ROCK kinases without significant off-target effects. Y-27632 is not recommended for diagnostic or medical purposes and requires careful handling to ensure reproducibility.

• Letrozole: Strategic Aromatase Inhibition for Translational

  2026-07-22

  This thought-leadership article examines the mechanistic, experimental, and translational dimensions of Letrozole, a potent non-steroidal aromatase inhibitor. We explore how Letrozole from APExBIO empowers breast cancer and neuroendocrine research, offering actionable guidance for translational workflows and protocol design. By contextualizing Letrozole within the competitive landscape of endocrine therapy—including a comparison with SERMs such as toremifene—we deliver strategic insights for researchers aiming to optimize estrogen pathway studies.

• Ribonuclease R (20 U/μL): Precision Tools for Circular RNA E

  2026-07-22

  Ribonuclease R (RNase R) (20 U/μL) from APExBIO enables highly selective linear RNA degradation, empowering advanced circular RNA enrichment and analysis. This article delivers evidence-based protocols, experimental troubleshooting, and expert insights for maximizing specificity, sensitivity, and reproducibility in RNA structure-function and biomarker studies.

• Valemetostat (DS-3201): Advanced Epigenetic Cancer Workflows

  2026-07-21

  Valemetostat (DS-3201) delivers unprecedented selectivity and potency for EZH2/EZH1 inhibition, enabling highly reproducible epigenetic modulation in lymphoma research. This guide details optimized protocols, troubleshooting strategies, and translational insights, ensuring researchers fully leverage Valemetostat's clinical and experimental capabilities.

• WZ4003 and NUAK1/2 Inhibition: Precision Tools for Tau and C

  2026-07-21

  Explore how WZ4003, a selective NUAK1/2 inhibitor, enables advanced and reproducible cell migration, proliferation, and tau phosphorylation assays. This article reveals new evidence-driven insights that refine experimental design for cancer and neurodegenerative research.

• DNase I (RNase-free): New Insights for High-Fidelity RNA Pre

  2026-07-20

  Discover how DNase I (RNase-free) enables unrivaled DNA removal for RNA extraction, in vitro transcription, and chromatin studies. This in-depth guide reveals new scientific perspectives and practical workflow optimizations for ribonuclease-free DNase I.

• HSC70–M Protein Interaction Drives TGEV Internalization via

  2026-07-20

  This study reveals that the membrane protein (M) of transmissible gastroenteritis virus (TGEV) directly interacts with host HSC70 to facilitate viral entry through clathrin-mediated endocytosis. The identification of HSC70 as a host factor in TGEV internalization highlights a novel target for antiviral strategies and broadens our understanding of coronavirus cell entry mechanisms.

• Phosbind Biotin LC: Protocol Guidelines for Phosphorylation

  2026-07-19

  Phosbind Biotin LC addresses the challenge of detecting phosphorylated proteins on PVDF membranes in Western Blot workflows where phospho-specific antibodies are inadequate or unavailable. It is not compatible with aqueous-only protocols or applications needing long-term storage of working solutions. This article outlines actionable parameters and best practices for applying this phosphate-binding reagent reliably.

• IDH2-Driven Metabolic Reprogramming Fuels CRC via HIF-1α Sta

  2026-07-18

  The referenced study uncovers how elevated IDH2 expression in colorectal cancer (CRC) cells drives metabolic reprogramming, promoting tumor progression through stabilization of HIF-1α signaling. By dissecting the effects of IDH2 inhibition on α-ketoglutarate levels and hypoxia pathways, this work reveals a metabolic vulnerability with implications for targeted CRC therapies.

451 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page